<DOC>
	<DOC>NCT00540618</DOC>
	<brief_summary>To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.</brief_summary>
	<brief_title>A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis</brief_title>
	<detailed_description>The primary objective of this study is to compare disease activity, as measured by PASI score, of three MEDI-507 dosing regimens (5 mg for 12 weeks, 5 mg for 6 weeks, 7 mg for 4 weeks) versus placebo administered weekly by SC injection.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Plaque psoriasis involving at least 10% of body surface area Age 18 through 65 years at the time of the first dose of study drug Both males and females are eligible. However, sexually active females, unless surgically sterile or at least 1 year postmenopausal, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of study drug and must agree to continue Currently receiving no therapy for psoriasis except emollients (certain other overthecounter products may be allowed with prior approval of the sponsor) Written informed consent obtained from the patient Ability to complete followup period of 167 days as required by the protocol Pustular, guttate, or erythrodermic psoriasis as the predominant disease type PASI score &lt;8 At screening (must be within 21 days before study entry) any of the following: lymphocyte count under 1,200 cells/mm3, WBC under 4,000 cells/mm3, hematocrit below 32%, platelets below 110,000 cells/mm3, creatinine, AST, ALT over 1.5 times upper limit of normal At screening (must be within 21 days before study entry) any clinical evidence of HIV, hepatitis B, hepatitis C or active hepatitis A infection Pregnancy (must have a negative serum pregnancy test within 21 days prior to the first dose of study drug, and urine pregnancy test must be negative on Study Day 0 before study entry) History of cancer (except excision of basal cell carcinoma) Any documented immunodeficiency A history of prior administration of monoclonal antibodies or related proteins Receipt of systemic retinoids, corticosteroids, cyclosporin A, methotrexate, phototherapy or coal tar treatment in the past 4 weeks Use of topical therapy (except emollients) for psoriasis in the past 2 weeks (certain other overthecounter products may be allowed with prior approval of the sponsor) Receipt of any investigational drug therapy within 6 weeks before the first dose of study drug in this protocol (use of licensed agents for indications not listed in the package insert is permitted) Current or planned participation in a research protocol in which an investigational agent or therapy may be administered Nursing mother Acute illness including infections 15. Clinical manifestations of significant end organ dysfunction or failure that may compromise the safety of the volunteer in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>